Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Receives Noncompliance Letter from Nasdaq

NEW YORK (GenomeWeb News) - Ciphergen Biosystems said last week that it has received a letter from Nasdaq indicating that it is not in compliance the exchange’s listing requirements.
 
Specifically, Nasdaq warned Ciphergen that it is not compliant with Marketplace Rule 4310(c)(3), which requires it to have a minimum of $2.5 million in stockholders' equity; $35 million market value of listed securities; or $500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years.
 
Ciphergen has 30 calendar days, or until Sept. 14, 2007, to regain compliance.
 
If the company doesn’t meet these requirements by that date, it faces delisting.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.